3 Engines and Gensets Maker, Fermentation Based Pharma Maker and Airline Software Company Stocks With a Strong Future Roadmap: Kirloskar Oil Engines, Concord Biotech and Accelya Solutions India

Engine, biotech and airline software stocks bring together companies with a visible plan for the years ahead. Kirloskar Oil Engines, Concord Biotech and Accelya Solutions India cover an engines and gensets maker, a fermentation based pharma maker and an airline software company.

This list covers three engine, biotech and airline software stocks with complete current figures: Kirloskar Oil Engines, Concord Biotech and Accelya Solutions India. Every figure comes from the latest reported financials and the 11 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Engine, Biotech and Airline Software Stocks?

Engine, biotech and airline software stocks are listed companies that build diesel engines and generator sets for farms, industry and backup power, make fermentation based active pharmaceutical ingredients and finished medicines, and provide revenue, fares and operations software to airlines. Their earnings depend on equipment demand, pharma sourcing and airline technology spending.

Engine, Biotech and Airline Software Stocks at a Glance

On valuation, Accelya Solutions India trades at a P/E below the industry P/E, while Kirloskar Oil Engines and Concord Biotech trade above it, which reflects the growth the market already expects. Readers comparing engine, biotech and airline software stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Engine, Biotech and Airline Software Stocks Have a Strong Roadmap in India?

Engine, biotech and airline software stocks have a strong roadmap in India because steady need for backup power and farm equipment, growing demand for specialty pharma ingredients and rising air travel keep widening the market for these companies.

• Engines and gensets. Farms and factories need reliable power.
• Fermentation pharma. Drug makers need dependable biotech inputs.
• Airline software. Airlines modernise fares and operations systems.

Why Kirloskar Oil Engines Features Among These Engine, Biotech and Airline Software Stocks

Among the engine, biotech and airline software stocks on this list, Kirloskar Oil Engines, based in Pune, makes diesel and gas engines, generator sets, pumps and power solutions for industrial, farm and infrastructure use.

The company has a return on equity of 15.9%, a debt to equity ratio of 1.48 and a market capitalisation of Rs 28,722 crore. The stock trades at a P/E of 53.7, above the industry P/E of 44.4.

Revenue rose from Rs 4,049 crore in FY22 to Rs 7,772 crore in FY26, a compound annual growth rate of 17.7%. Net profit grew from Rs 171 crore in FY22 to Rs 558 crore in FY26, which works out to a compound annual growth rate of 34.4%. In the June 2026 quarter, revenue grew 12.1% year on year to Rs 2,015 crore.

Roadmap: Backup power demand from data centres, telecom and infrastructure, a growing exports business and new alternative-fuel engines give it several tracks for growth. A large service network helps it hold on to customers across product cycles.

What to watch: Watch order intake from data centres and the pace of new product launches in cleaner fuels.

Why Concord Biotech Features Among These Engine, Biotech and Airline Software Stocks

Among the genset maker, drug ingredient and fare system shares on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.

Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%.

In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0.

Roadmap: The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.

What to watch: Monitor the pace of new product introductions and the contribution from formulations.

Why Accelya Solutions India Features Among These Engine, Biotech and Airline Software Stocks

Among the three companies on this list, Accelya Solutions India provides software and services to airlines, helping them manage revenue accounting, sales settlement and passenger-related processes for carriers around the world.

Revenue rose from Rs 376 crore in FY22 to Rs 553 crore in FY26, a compound annual growth rate of 10.1%. Net profit grew from Rs 76.2 crore in FY22 to Rs 95.4 crore in FY26, which works out to a compound annual growth rate of 5.8%.

The company has a return on equity of 38.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 1,422 crore. The stock trades at a P/E of 15.0, below the industry P/E of 17.6.

Roadmap: The company benefits from airlines modernising their technology and from strong growth in air travel. Long-term contracts with carriers provide repeat revenue.

What to watch: Follow new airline contracts, global air traffic and the pace of product upgrades.

Kirloskar Oil Engines vs Concord Biotech vs Accelya Solutions India on Key Financials

The table below sets the three engine, biotech and airline software stocks side by side on revenue, profit and margin, using reported figures.

Accelya Solutions India posts the highest return on equity in this group at 38.1%. Kirloskar Oil Engines combines the largest FY26 revenue at Rs 7,772 crore with the fastest revenue growth, a 17.7% compound annual rate. A useful habit with engine, biotech and airline software stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Engine, Biotech and Airline Software Stocks

Every theme carries risks that deserve a check before any decision. For these engine, biotech and airline software stocks, the main points are: Long-term genset maker, drug ingredient and fare system shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Production cycles. Vehicle output can vary with demand.
• Regulatory approvals. Plant inspections and approvals can affect supplies.
• Travel cycles. Bookings and occupancy follow travel demand.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter engine, biotech and airline software stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Engine, Biotech and Airline Software Stocks

Engine, biotech and airline software stocks suit investors who prefer to study business strength before price moves. Kirloskar Oil Engines, Concord Biotech and Accelya Solutions India each have a clear plan to grow. Based on the 11 November 2026 close, Kirloskar Oil Engines trades at Rs 1,632.4, Concord Biotech at Rs 597.2 and Accelya Solutions India at Rs 972.7.

Download the Univest iOS App or Univest Android App to track engine, biotech and airline software stocks, set price alerts and get research-backed stock ideas.

What are engine, biotech and airline software stocks?

Ans. Engine, biotech and airline software stocks are listed companies that build diesel engines and generator sets for farms, industry and backup power, make fermentation based active pharmaceutical ingredients and finished medicines, and provide revenue, fares and operations software to airlines. Their earnings depend on equipment demand, pharma sourcing and airline technology spending. This list looks at three of them, Kirloskar Oil Engines, Concord Biotech and Accelya Solutions India, using reported FY22 to FY26 financials and the 11 November 2026 closing prices.

Which engine, biotech and airline software stocks are covered in this list?

Ans. This list covers Kirloskar Oil Engines, Concord Biotech and Accelya Solutions India. Based on the 11 November 2026 close, Kirloskar Oil Engines traded at Rs 1,632.4, Concord Biotech at Rs 597.2 and Accelya Solutions India at Rs 972.7. Their return on equity ranges from 12.9% to 38.1%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.1% to 17.7%.

Why do engine, biotech and airline software stocks have a strong future roadmap in India?

Ans. Engine, biotech and airline software stocks have a strong roadmap in India because steady need for backup power and farm equipment, growing demand for specialty pharma ingredients and rising air travel keep widening the market for these companies. The main drivers are as follows. Engines and gensets. Farms and factories need reliable power. Fermentation pharma. Drug makers need dependable biotech inputs. Airline software. Airlines modernise fares and operations systems. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Kirloskar Oil Engines performed financially?

Ans. Revenue rose from Rs 4,049 crore in FY22 to Rs 7,772 crore in FY26, a compound annual growth rate of 17.7%. Net profit grew from Rs 171 crore in FY22 to Rs 558 crore in FY26, which works out to a compound annual growth rate of 34.4%. In the June 2026 quarter, revenue grew 12.1% year on year to Rs 2,015 crore. The company has a return on equity of 15.9%, a debt to equity ratio of 1.48 and a market capitalisation of Rs 28,722 crore. The stock trades at a P/E of 53.7, above the industry P/E of 44.4. Looking ahead, backup power demand from data centres, telecom and infrastructure, a growing exports business and new alternative-fuel engines give it several tracks for growth. A large service network helps it hold on to customers across product cycles.

How has Concord Biotech performed financially?

Ans. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.

How has Accelya Solutions India performed financially?

Ans. Revenue rose from Rs 376 crore in FY22 to Rs 553 crore in FY26, a compound annual growth rate of 10.1%. Net profit grew from Rs 76.2 crore in FY22 to Rs 95.4 crore in FY26, which works out to a compound annual growth rate of 5.8%. The company has a return on equity of 38.1%, a debt to equity ratio of 0.06 and a market capitalisation of Rs 1,422 crore. The stock trades at a P/E of 15.0, below the industry P/E of 17.6. Looking ahead, the company benefits from airlines modernising their technology and from strong growth in air travel. Long-term contracts with carriers provide repeat revenue.

What risks should investors check before buying engine, biotech and airline software stocks?

Ans. Investors should check a few risks before buying engine, biotech and airline software stocks. Production cycles. Vehicle output can vary with demand. Regulatory approvals. Plant inspections and approvals can affect supplies. Travel cycles. Bookings and occupancy follow travel demand. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of engine, biotech and airline software stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 11 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.